<SEC-DOCUMENT>0001968582-25-000983.txt : 20251007
<SEC-HEADER>0001968582-25-000983.hdr.sgml : 20251007
<ACCEPTANCE-DATETIME>20251007161107
ACCESSION NUMBER:		0001968582-25-000983
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251007
DATE AS OF CHANGE:		20251007

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Akero Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001744659
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-38944
		FILM NUMBER:		251379962

	BUSINESS ADDRESS:	
		STREET 1:		601 GATEWAY BOULEVARD, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-487-6488

	MAIL ADDRESS:	
		STREET 1:		601 GATEWAY BOULEVARD, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Rolph Timothy
		CENTRAL INDEX KEY:			0001779479
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		144

	MAIL ADDRESS:	
		STREET 1:		C/O AKERO THERAPEUTICS, INC.
		STREET 2:		601 GATEWAY BOULEVARD, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <!-- Generated by Workiva -->
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001779479</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001744659</issuerCik>
      <issuerName>Akero Therapeutics</issuerName>
      <secFileNumber>001-38944</secFileNumber>
      <issuerAddress>
        <com:street1>601 Gateway Blvd., Suite 350</com:street1>
        <com:city>South San Francisco</com:city>
        <com:stateOrCountry>CA</com:stateOrCountry>
        <com:zipCode>94080</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>650-487-6488</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Timothy Rolph</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Officer</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>J.P. Morgan Securities LLC</name>
        <address>
          <com:street1>390 Madison Avenue</com:street1>
          <com:street2>6th Floor</com:street2>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10017</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>56369</noOfUnitsSold>
      <aggregateMarketValue>2595229</aggregateMarketValue>
      <noOfUnitsOutstanding>79988975</noOfUnitsOutstanding>
      <approxSaleDate>10/07/2025</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>10/07/2025</acquiredDate>
      <natureOfAcquisitionTransaction>Stock Option Exercise</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>56369</amountOfSecuritiesAcquired>
      <paymentDate>10/07/2025</paymentDate>
      <natureOfPayment>Compensation</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Timothy Rolph</name>
        <address>
          <com:street1>C/o Akero Therapeutics, Inc.</com:street1>
          <com:street2>601 Gateway Boulevard, Suite 350</com:street2>
          <com:city>South San Francisco</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94080</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <saleDate>08/05/2025</saleDate>
      <amountOfSecuritiesSold>12500</amountOfSecuritiesSold>
      <grossProceeds>616299</grossProceeds>
    </securitiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Timothy Rolph</name>
        <address>
          <com:street1>C/o Akero Therapeutics, Inc.</com:street1>
          <com:street2>601 Gateway Boulevard, Suite 350</com:street2>
          <com:city>South San Francisco</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94080</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <saleDate>09/08/2025</saleDate>
      <amountOfSecuritiesSold>12500</amountOfSecuritiesSold>
      <grossProceeds>552135</grossProceeds>
    </securitiesSoldInPast3Months>
    <remarks>The sales under this filing are from Cashless Option Exercises that will occur within 3 months from the date of this filing.</remarks>
    <noticeSignature>
      <noticeDate>10/07/2025</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>08/12/2024</planAdoptionDate>
      </planAdoptionDates>
      <signature>/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Timothy Rolph</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
